A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women

NCT ID NCT06402383

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests two strategies for preventing cervical cancer in women living with HIV in Tanzania. Both strategies involve HPV self-sampling and visual checks of the cervix, but they differ in the timing of HPV vaccination. The study aims to see which approach better reduces precancerous lesions at a 12-month follow-up, potentially informing national screening programs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HPV vaccine (offered alongside HPV DNA testing and visual assessment of the cervix)
What this could lead to
If successful, this could establish a practical, effective strategy for preventing cervical cancer in women living with HIV, potentially reducing cervical cancer rates in Tanzania and similar settings.
What could go wrong
The trial is early-stage and may face challenges in implementation, such as adherence to follow-up visits. The vaccine's benefit in women already exposed to HPV is uncertain, and outcomes may not generalize beyond the study population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pamoja Tunaweza Women's Centre

    Moshi, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.